Martin Vodička
Martin Vodička has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ilja Ryšavý
Department of Internal Medicine, Tomas Bata Hospital Zlin
1 shared publication - Josef Klhůfek
Department of Clinical Pharmacy, Tomas Bata Hospital Zlin
1 shared publication - Martin Fajkus
Faculty of Applied Informatics, Tomas Bata University in Zlín
1 shared publication - Martin Šíma
Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
1 shared publication - Ondřej Slanař
Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
1 shared publication - Terezie Macková
Department of Clinical Pharmacy, Tomas Bata Hospital Zlin, 762 75 Zlin, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia
1. Spironolactone, a synthetic steroidal antagonist of the mineralocorticoid receptor, was first synthesized in 1957 [1]. Since its introduction into clinical practice, it has become an essential t...
- 17 September 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Open AccessBiochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia
1. Spironolactone, a synthetic steroidal antagonist of the mineralocorticoid receptor, was first synthesized in 1957 [1]. Since its introduction into clinical practice, it has become an essential t...
- Open Access
- 29 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 929
Population Pharmacokinetic Modeling of Intravenous Fluconazole to Inform eGFR-Based Dosing: A Simulation Study Demonstrating Superiority over Standard Regimens
Aim: This study aimed to develop a population pharmacokinetic (PK) model of intravenous fluconazole and, using model-based simulations, propose initial dosing recommendations that optimize efficacy while limiting toxicity. Methods: Therapeutic drug monitoring data from 116 adult patients (183 serum concentrations) treated with intravenous fluconazole between 2022 and 2025 at a single center were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were applied to identify dosing strategies that maximize the probability of achieving the PK/PD efficacy target. Results: Estimated glomerular filtration rate (eGFR) was the strongest predictor of fluconazole clearance, and adjusted body weight (ABW) influenced the volume of distribution. For a patient with ABW of 75 kg and eGFR of 90 mL/min, the estimated volume of distribution and clearance were 41.6 L and 0.81 L/h, respectively. An eGFR-based dosing nomogram was developed, and simulations demonstrated that this approach outperformed standard dosing regimens in achieving the PK/PD target. Conclusions: These findings suggest an initial loading dose (2.8 times the maintenance dose) followed by individualized, eGFR-guided maintenance dosing to enhance the safety and efficacy of intravenous fluconazole therapy; however, prospective clinical validation is required before routine clinical implementation.
- 29 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 929
Open AccessPopulation Pharmacokinetic Modeling of Intravenous Fluconazole to Inform eGFR-Based Dosing: A Simulation Study Demonstrating Superiority over Standard Regimens
Aim: This study aimed to develop a population pharmacokinetic (PK) model of intravenous fluconazole and, using model-based simulations, propose initial dosing recommendations that optimize efficacy while limiting toxicity. Methods: Therapeutic drug monitoring data from 116 adult patients (183 serum concentrations) treated with intravenous fluconazole between 2022 and 2025 at a single center were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were applied to identify dosing strategies that maximize the probability of achieving the PK/PD efficacy target. Results: Estimated glomerular filtration rate (eGFR) was the strongest predictor of fluconazole clearance, and adjusted body weight (ABW) influenced the volume of distribution. For a patient with ABW of 75 kg and eGFR of 90 mL/min, the estimated volume of distribution and clearance were 41.6 L and 0.81 L/h, respectively. An eGFR-based dosing nomogram was developed, and simulations demonstrated that this approach outperformed standard dosing regimens in achieving the PK/PD target. Conclusions: These findings suggest an initial loading dose (2.8 times the maintenance dose) followed by individualized, eGFR-guided maintenance dosing to enhance the safety and efficacy of intravenous fluconazole therapy; however, prospective clinical validation is required before routine clinical implementation.